Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Doc Bones who wrote (8400)	5/19/2003 12:21:49 PM
From: tom pope	Read Replies (1) \| Respond to of 52153

I guess there was nothing else to do other than 'fess up to a blunder 12:12 ET DNA Genentech upgraded at BofA (53.32 +15.42) -- Update -- In a note entitled "Holy Cow! Our Timing Couldn't Have Been Worse", Banc of America reversed themselves and upgraded DNA to Buy from Sell following this morning's surprise Avastin news (see the 7:17 comment for the news and 7:29 for BofA's pre-open downgrade); firm says each $100 mln in Avastin sales equates to roughly $0.10 per share, and believes Avastin possesses billion-dollar potential, will enjoy rapid adoption, and should enjoy several years free from competition (CEPH, IMCLE, REGN, AZN, NVS, and MEDI have competing drugs in Phase I/II testing). Raises price target to $73 from $30.